The EPS projection of FibroGen, Inc (NASDAQ:FGEN) for period quarter completed 2016-12-31 is $-0.68.
The EPS estimates pronounced a week and 30 days ago were $-0.68 and $-0.68 correspondingly. The EPS forecasts specified 60 and 90 days before were $-0.68 and $-0.68 respectively. From a week ago, the aberration in EPS forecast is 0 percent.
The mean EPS prediction straightaway before the earnings release for the quarter completed 2 is $-0.68 based on 4 EPS estimations. The EPS stated on 2016-08-08 was $0.35. The EPS surprise was $0.02, or 6.06 percent. The standard deviation as per known EPS estimates was $0.13.
The positive EPS revisions were 0 a week earlier and negative revisions were 0. In last 30 and 60 days, the positive EPS revisions were 0 and 2 correspondingly, while for 90 and 120 days, revisions count was 2 and 2.
The negative revisions of per-share earnings in the last 30 and 60-days were 0 and 1 in that order. however, for 90 and 120 days’ period, the count was 1 and 1 in that order.
EPS revisions upgrade and downgrade in the last 18 days were 0 and 2 correspondingly.
Quarterly Sales Estimates
The arithmetic mean of probable annual sales of FibroGen, Inc (NASDAQ:FGEN) is $21.303 and the median was $24.84. The estimate is stated by 3 analysts for the fiscal 2016.
The highest annual projection is $25.07 and lowest sales target is $14. This marks a standard deviation of $6.325.
Almost 3 have given revised positive sales forecast in the past week and 3 have downgraded forecasts. As per the stated estimates, the change in target from the past week is 0 percent.
Nearly 3 have revised sales projections in positive side over the past month and 3 have downgraded forecasts. This shows a mean estimate deviation of 0 percent.
Just about 3 have revised sales forecast on plus side over the quarter and 3 have downgraded forecasts. This shows mean estimate deviation of 10.452 percent.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...